H.C. Wainwright Reaffirms Buy On Synthetic Biologics, Sees 186% Upside
In a research report published today, H.C. Wainwright analyst Andrew Fein reaffirmed a Buy rating on Synthetic Biologics (NYSE:SYN) with a $4 price target, which represents a 186% upside from where the stock is currently trading.
Fein wrote, “Key inflections that will drive value for SYN in 2015 are centered on Trimesta for relapse remitting multiple sclerosis (RRMS) in women and SYN-004, a prophylactic for C. Difficile infection, in our opinion. The ultimate value of Trimesta is hinged on the topline data from the structural MRI analysis expected 1Q15.”
The analyst continued, “While SYN did meet their primary and secondary outcome measures in the investigator initiated Phase 2 study of Trimesta in RRMS, we believe that MRI data correlating functional outcomes to structural changes would facilitate a partnership and thus the path to a larger Phase 3 study. The company’s second value driver, SYN-004, a prophylactic therapeutic for C. difficile infection, is expected to enter phase 1a and phase 1b studies within the next 30 days, with topline top line data before year end.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Andrew Fein has a total average return of 6.2% and a 32.5% success rate. Fein has a -3.4% average return when recommending SYN, and is ranked #1083 out of 3393 analysts.